We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
27 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Vaxchora (vibrio cholerae) vaccine has been approved for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older travelling to cholera-affected countries.
-
Australian Public Assessment Report (AusPAR)Nuvaxovid (SARS-CoV-2 rS [NVX-CoV2373]) COVID-19 vaccine has been approved for the prevention of coronavirus disease 2019 (COVID-19) caused by SARSCoV-2 in individuals 12 years of age and older.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Vaxchora Vibrio cholerae bacteria cells (CVD 103-HgR strain) 4 x 10^8 to 2 x 10^9 CFU suspension, powder for, sachet.
-
Australian Public Assessment Report (AusPAR)Nuvaxovid (SARS-CoV-2-rS), a vaccine against SARS-CoV-2, has been approved for the prevention of COVID-19.
-
Prescription medicine decision summaryVaxchora (vibrio cholerae) is approved to prevent disease caused by Vibrio cholerae serogroup O1 in those travelling to cholera-affected countries.
-
Prescription medicine registrationActive ingredients: Vibrio cholerae.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for NUVAXOVID (SARS-CoV-2 rS [NVX-CoV2373]) COVID-19 VACCINE adjuvanted suspension for injection vial.
-
Australian Public Assessment Report (AusPAR)Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.
-
Prescription medicine registrationActive ingredients: SARS-CoV-2 rS (NVX-CoV2373).
-
COVID-19 test kitAntigen Test - Intended for use: Point-of-care